Birgitte Rønø | Chief Scientific Officer
Evaxion Biotech A/S

Birgitte Rønø, Chief Scientific Officer, Evaxion Biotech A/S

Birgitte Rønø joined Evaxion in 2017 and was appointed Chief Science Officer in 2021. Dr. Rønø has more than 20 years' experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte Rønø served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise.


Day 3 - Thursday 31st October @ 09:45

Personalized cancer vaccines beyond neoantigens - Title TBC

last published: 10/Jul/24 14:15 GMT

back to speakers